Opinion|Videos|December 23, 2024
Examining Axatilimab in the AGAVE-201 Trial For cGVHD
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses how the mechanism of action of axatilimab, recently approved by the FDA for chronic graft-vs-host disease (cGVHD), involves targeting CSF1R to disrupt macrophage differentiation and reduce inflammation, and how the AGAVE-201 trial demonstrated strong efficacy and safety, which will influence clinical decision-making and potentially change the GVHD treatment landscape by offering a novel therapeutic option.
Advertisement
Video content above is prompted by the following:
- What did this abstract elucidate about the mechanism of action of axatilimab, which was approved by the FDA this year as a treatment for chronic graft-vs-host disease (cGVHD)?
- How will this abstract affect your clinical decision-making?
- The AGAVE-201 trial led to the approval of axatilimab for cGVHD. Discuss the methods and study design of this trial.
- What were the key efficacy and safety data seen in the AGAVE-201 trial with axatilimab?
- How do these results influence your clinical practice?
- How do you see the GVHD treatment landscape changing with the introduction of axatilimab?
Advertisement
Related to this article
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.
A systematic review found vitamin D did not consistently reduce MS relapse rates, though some studies reported lower MRI lesion activity.
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
Insurance Barriers Tied to Missed Long-Acting PrEP Starts
4
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
5